Weight-loss drugs. Who pays?

<p>GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.</p><p>Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.</p><p>But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.</p><p>In this …